홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-3.64%
월간 변동
-4.50%
6달 변화
-43.32%
년간 변동율
-48.29%
이전 종가
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
양
6
마켓
주식
헬스케어
TCRX
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
18.76 M
19.08 M
43.61 M
52.31 M
—
Valuation ratios
Enterprise value
-53.51 M
-4.54 M
662.44 M
324.42 M
602.51 M
Price to earnings ratio
—
-0.62
-4.2
-2.67
-6.93
Price to sales ratio
—
3.04
17.8
120.9
212.92
Price to cash flow ratio
—
0.62
6.1
3.07
7.61
Price to book ratio
—
0.41
2.48
1.41
2.08
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.26
0.33
0.33
0.34
0.46
Return on equity %
0.3
0.67
0.59
0.53
0.77
Return on invested capital %
687.92
585.8
537.56
686.88
—
Gross margin %
100
100
100
100
400
Operating margin %
479.65
492.32
444
4 787.68
9 922.53
EBITDA margin %
—
—
—
—
—
Net margin %
479.49
489.26
423.86
4 527.66
9 580.2
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.76
7.17
6.51
8.14
30.19
Inventory turnover
—
—
—
—
—
Asset turnover
0.05
0.07
0.09
0.01
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
0.15
0.1
0.09
0.41
Long term debt to total equity ratio
—
0.29
0.18
0.13
0.69
Per share metrics
Operating cash flow per share
—
2.77
0.94
0.99
1.04
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
4.99
2.93
2.59
7.63
Net current asset value per share
—
5.16
2.96
2.61
7.73
Tangible book value per share
—
4.13
2.3
2.15
6.24
Working capital per share
—
4.44
2.51
2.29
6.72
Book value per share
—
4.13
2.3
2.15
6.24
뉴스
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan 테라퓨틱스, ASH 행사 후 BTIG ’중립’ 등급 유지
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
모건 스탠리, Tscan Therapeutics 주식 투자의견 강등
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Tscan Therapeutics Q3 실적, 수익 예상치를 넘어